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Abstract
Objectives This study responds to a request in the National
Institute for Health and Care Excellence (NICE) guidance
to assess the impact of using alternative sources of utility
values, applied to multiple sclerosis (MS).
Methods Incremental cost-effectiveness ratios (ICERs)
were calculated using utility values based on UK and
Dutch values of EQ-5D, two UK mappings and one Dutch
mapping of EQ-5D and two condition-specific instruments:
the UK eight-dimensional Multiple Sclerosis Impact Scale
(MSIS-8D) and the Dutch Multiple Sclerosis Impact Scale
Preference-Based Measure (MSIS-PBM). Deterministic
and Monte-Carlo simulation-based ICERs were estimated
for glatiramer acetate versus symptom management using a
lifetime Markov model.
Results For both UK and Dutch perspectives, mapped and
condition-specific utility values expressed significantly
higher quality of life for the worst health state of the model
than did EQ-5D. The ICER of glatiramer acetate with EQ-
5D was US$182,291 for The Netherlands and US$153,476
for the UK. Ratios for mapped and condition-specific
utilities were between 20 and 60 % higher.
Conclusion The overestimation of quality of life of
patients with MS by mapped EQ-5D or condition-specific
utility values, relative to observed EQ-5D, increases the
ICER substantially in a lifetime Markov model.
Key Points for Decision Makers
The currently available mappings and condition-
specific preference-based instruments can result in
incremental cost-effectiveness ratios at least 20 %
higher than those based on EQ-5D in a lifetime
model for multiple sclerosis (MS).
Health technology assessment bodies should be
aware that the different instruments to measure
utilities in MS can result in rather different outcomes
when applied in cost-utility analyses.
1 Introduction
Multiple sclerosis (MS) is a severely debilitating neuro-
logical condition affecting approximately 126,669 people
in the UK, with about 6000 new cases each year [1].
Improvement of quality of life is a key treatment goal for
this progressive condition, with limited impact on mortal-
ity. New pharmacological treatments that can improve the
quality of life of patients with MS have to demonstrate a
favourable outcome in economic evaluations before being
eligible for reimbursement in both the UK and The
Netherlands. In these economic evaluations, the health
benefit of new pharmacological treatments is assessed with
the quality-adjusted life-year (QALY). Computing health
benefit with QALYs requires information on length of life
and health-related quality of life (HR-QOL) in the form of
utility values. HR-QOL can be measured with several
instruments, of which EQ-5D is one of the most widely
used. This study responds to a request in the National
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Institute for Health and Care Excellence (NICE) guidance
(paragraph 5.3.10 in the guidance [2] and section 2.4 of
Technical Support Document 11 [3]) to assess the impact
on incremental cost-effectiveness ratios (ICERs) of using
alternative sources of utility values (observed EQ-5D,
mapped EQ-5D and condition-specific instruments) for
economic evaluations in MS.
In the UK, NICE prefers EQ-5D-based utilities as a
measure of HR-QOL. According to the NICE guidance,
‘‘when EQ-5D data are not available, these data can be
estimated by mapping (…)’’ (paragraph 5.3.9) [2]. Also,
when EQ-5D is not considered themost appropriate measure
of HR-QOL, and when this consideration is substantiated
with empirical data, alternatives to EQ-5D can be accepted,
which is further described in Technical Support Document
11 [3]. For both alternatives to directly observedEQ-5Ddata,
the guidance calls for an assessment of using the alternative
source of utility on the outcomes of the economic evaluation.
Such an assessment is often complicated as EQ-5D is absent
or less appropriate by definition when the alternatives are
applied. The newDutch guidelines for economic evaluations
put an ever greater emphasis on EQ-5D than the UK guide-
lines. Alternatives to EQ-5D may be accepted, but even
when EQ-5D is demonstrably not appropriate, alternative
sources of utility values have to be presented alongside a
base-case analysis that includes EQ-5D [4].
The preference of reimbursement authorities for one
single generic preference-based measure as source of utility
values has benefits in terms of achieving a uniform and
comparable assessment of benefit. In case EQ-5D is absent,
mapping to EQ-5D is preferred as this replicates EQ-5D data
and contributes to this uniform assessment. However, the
advantage of a uniform assessment comes at the potential
cost of having a measure that is targeted at those elements of
quality of life that are not targeted or ‘‘relevant and sensitive
to those things that matter to patients with the condition’’ [5].
For example, fatigue and problems with cognition are not
directly included in EQ-5D [6], while both are important
symptoms for MS patients [7]. Therefore, two MS-specific
preference-based measures developed in the past 5 years
include an item on ‘‘feeling mentally fatigued’’ [6, 8]. It is
uncertain, however, if alternatives to EQ-5D might be too
focused on MS and may therefore miss important adverse
effects or co-morbidities [5]. In other words, MS-specific
instrumentsmay be ‘too specific’ for an adequate assessment
of the benefit of treatments in terms of HR-QOL.
To assess if a new condition-specific instrument has
merit, the psychometric properties are compared with
existing generic instruments such as EQ-5D to show
increased sensitivity. What receives less attention, how-
ever, is that the ultimate goal of these instruments is to
calculate QALYs for economic evaluations. As a
consequence, it is often overlooked that improvements in
psychometric properties (i.e. favourable statistical proper-
ties such as larger effect sizes) might not be very relevant
in the context of health economic modelling.
The evidence regarding the performance of the utility
instruments available for MS can be summarised as fol-
lows: EQ-5D has limited discriminant validity for the
middle Expanded Disability Status Scale (EDSS) cate-
gories, while mapped and condition-specific utilities have a
floor effect compared with EQ-5D for patients in poor
health. The three-level version of EQ-5D has limited dis-
criminatory power between different categories of the
EDSS, such as categories 3 and 4 [9] and categories 3–5,
while it has been shown that the physical scale of the
29-item Multiple Sclerosis Impact Scale (MSIS-29) was
able to discriminate between these categories [10]. These
observations are confirmed in a large multi-country study
[11]. The first alternative to EQ-5D is mapping, which only
applies when EQ-5D is considered appropriate, something
that is uncertain in MS. For MS, mapping algorithms have
been developed and tested for the prediction of Dutch and
UK utilities; these general show good performance but
over-predict the utility values of patients in poor health
[10, 12]. The second alternative to EQ-5D is a condition-
specific instrument, two of which exist for MS: the Dutch
Multiple Sclerosis Impact Scale Preference-Based Measure
(MSIS-PBM) [8] and the UK eight-dimensional Multiple
Sclerosis Impact Scale (MSIS-8D) [6]. The MSIS-PBM
showed increased sensitivity at the cost of a limited capa-
bility to describe patients in poor health compared with
EQ-5D [8]. Also, the lowest score on the MSIS-PBM was
0.42, which is high compared with the lowest score of the
EQ-5D which was –0.329 (using the Dutch tariff) [13]. The
MSIS-8D has a lowest attainable utility value of 0.08 but
the instrument displays a ceiling effect compared with EQ-
5D, as the best attainable value is 0.88 versus 1 with EQ-
5D for patients in full health.
Based on the available evidence, all instruments that are
currently available to calculate QALYs in MS have dif-
ferent properties and associated measurement issues. This
study investigates how the properties of each of the
instruments impact on the ICER of an economic evaluation
in MS.
2 Methods
Economic evaluations of new treatment strategies for MS
often use Markov models with health states based on EDSS
categories [14–16]. For this study, the model structure,
costs, effects and transition probabilities were taken from
Bell et al. [16]. The model compares symptom
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management with subcutaneous glatiramer acetate in MS
patients with relapsing-remitting MS. First, utility values
were calculated using data from the UK Multiple Sclerosis
Risk-Sharing Scheme Monitoring Study, based on EQ-5D
(Dutch and UK tariff), a mapping to Dutch EQ-5D utility
values and two mappings to UK EQ-5D utility values, and
the Dutch MSIS-PBM and UK MSIS-8D. Then, these
utility values were applied to the health states of the
Markov model. Seven ICERs were calculated, one for each
of the instruments for Dutch and UK utilities.
2.1 Data Sources
This study combines a published Markov model with cross-
sectional utility data (n = 1295) calculated using data from
the UK risk-sharing monitoring scheme [17] using patient
responses to EQ-5D andMSIS-29 questionnaires (detailed in
Sects. 2.3.1 and 2.3.2). The cross-sectional data were col-
lected from MS patients in 70 specialist centres in the UK.
2.2 Markov Model
The Markov model was based on a previously published
model [16]. The model has a 1-month cycle length, a
lifetime time horizon and seven health states: four EDSS-
based health states, referred to as EDSS1 (EDSS score
0–2.5), EDSS2 (EDSS score 3–5.5), EDSS3 (EDSS score
6–7.5) and EDSS4 (EDSS score 8–9.5), two relapse health
states differing in severity, and death. The model structure
is depicted in Fig. 1. Medical management is compared to
subcutaneous glatiramer acetate, which is only prescribed
to patients in the EDSS1 and EDSS2 health states or for
relapses experienced during those health states. The treat-
ment effect was expected to reduce the probability of
relapses as well as reduce the progression of the disease.
The ICERs produced here should be interpreted in relative
terms not absolute terms, as not all model aspects could be
derived from the original publication. A description of the
model and its parameters is provided in the Electronic
Supplementary Material.
2.3 Sources of Utility Values for Quality-Adjusted
Life-Year Calculation
The calculation of QALYs requires an assessment of length
of life and HR-QOL. Here, six sources of values for HR-
QOL are described: the EQ-5D with UK and Dutch values,
mapped EQ-5D for UK and Dutch values, and two con-
dition-specific preference-based instruments, one for the
UK and one for The Netherlands. All instruments were
applied in the same risk-sharing scheme monitoring study
database.
Utility values were calculated by applying the utility
algorithms described in the following sections to the
patient data of the UK risk-sharing monitoring scheme.
Only patients that had data for all utility instruments were
included. The mean and standard error (SE) for the four
EDSS-based health states were then derived by clustering
patients in four EDSS-based groups following the EDSS
coding of the Markov model described in Sect. 2.2. The
derived values were then applied to the Markov model to
calculate QALYs. For the two relapse states, the same
procedure as applied in the original publication of the
Markov model was used; each relapse state was assigned a
utility that was 0.094 lower than the mean utility of the
state from which the patient entered the relapse state (i.e.
EDSS1 or EDSS2). Quality of life was assumed equal for
patients receiving symptom management and patients
receiving subcutaneous glatiramer acetate staying in the
same health state, which means that the QALYs gained due
to treatment were gained only due to delayed disease
progression.
2.3.1 EQ-5D
The EQ-5D is a generic preference-based measure. It
measures HR-QOL by asking patients how they feel today
and scores health on five dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression.
The five dimensions have three answer categories, so the
instrument can distinguish between 243 health states.
EDSS 0.0–2.5 EDSS 3.0–5.5 EDSS 6.0–7.5 EDSS 8.0–9.5 
Relapse mild Relapse severe Death
Fig. 1 Markov model structure.
EDSS Expanded Disability
Status Scale
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Utility values are calculated by applying country-specific
algorithms (‘tariff’) to the five-dimensional health profile.
The tariff for this algorithm was developed by deriving
utility values for 17 (Dutch tariff) and 42 (UK tariff) out of
243 health states in a valuation study with 298 (Dutch
tariff) and 2997 (UK tariff) respondents from the general
population using the time trade-off (TTO) method. The
health state values of the states not included in the TTO
study were estimated using regression techniques [13, 18].
The current study uses values from the three-level version
of EQ-5D as the new five-level version was not included in
the Multiple Sclerosis Risk Sharing Scheme Monitoring
Study from which data was included. The range of the
utility values of EQ-5D is 1 to –0.59 for the UK tariff [18]
and 1 to –0.39 for the Dutch tariff [13].
2.3.2 29-Item Multiple Sclerosis Impact Scale (MSIS-29)
The MSIS-29 measures the physical and psychological
impact of MS using a self-reported questionnaire consisting
of 29 items [19]. The instrument is currently in its second
version, which consists of the same 29 items as version 1
but has four answer categories rather than five, following
extensive psychometric testing of the first version using
item response theory [20]. Version 2 of the MSIS-29 has
removed answer category 4 ‘quite a bit’ from version 1.
Both versions of MSIS-29 consist of two subscales, a
physical impact scale (items 1–20) and a psychological
impact scale (items 21–29).
For this study, utility algorithms based on both version 1
and version 2 are used, but only data for version 1 are
available. Therefore, MSIS-29 version 1 was transformed
to version 2 by merging the answer categories ‘quite a bit’
and ‘moderately’. For version 1 to resemble version 2, the
‘quite a bit’ answers could be merged with either of the two
adjacent levels 3 or 5. A Rasch analysis of the instrument
by its developers showed that for both the physical impact
scale and the psychological impact scale, it was hardest for
respondents to distinguish between categories 2, 3 and 4
[20]. This suggests that it is more sensible to merge answer
category 4 (‘quite a bit’) with answer category 3 (‘mod-
erately’) than with category 5 (‘extremely’) when applying
the algorithm for the MSIS-29 based on version 2 of the
instrument.
The MSIS-29 has been converted to an instrument that
can be used to calculate QALYs through mapping and
direct valuation with TTO, as described below.
2.3.2.1 MSIS-29 Mapped on EQ-5D A simple search
strategy was deployed in EMBASE and PubMed to identify
mapping algorithms from MSIS-29 to EQ-5D using the
search terms [‘eq 5d’ OR eq5d AND mapping AND ‘msis
29’ OR msis29] for EMBASE and [(eq-5D or eq5d) and
mapping and (msis-29 or msis29)] for PubMed. The
EMBASE search identified 14 publications, of which two
were mapping studies. The PubMed search identified two
publications, which were the same as those identified in
EMBASE: Versteegh et al. [10] and Hawton et al. [12].
The mapping by Versteegh et al. [10] included mapping to
Dutch and UK EQ-5D utilities. The mapping by Hawton
et al. [12] mapped to UK EQ-5D utilities. Hence, three
published mapping algorithms were applied to estimate UK
and Dutch EQ-5D utilities.
The mapping by Versteegh et al. [10] used data from the
UK risk-sharing monitoring scheme to estimate both Dutch
and UK EQ-5D utilities from MSIS-29 version 1. The
ordinary least squares (OLS) algorithm was developed
using a randomly drawn subsample of the UK risk-sharing
monitoring scheme (n = 661) and was validated on two
subsamples of the same dataset (n = 339 and n = 295).
The final algorithms used nine (Dutch) and ten (UK) items
of the MSIS-29 and a constant term to predict EQ-5D
utilities, and did so without significant differences between
observed and estimated values; however, subgroup analysis
showed noticeable over-prediction of the utility values of
patients in poor health.
The mapping by Hawton et al. [12] used data from the
UK South West Impact of Multiple Sclerosis (SWIMS)
Project, which contains version 2 of the MSIS-29. The
estimation sample (n = 672) was used to test a range of
mapping strategies. Predictive performance was subse-
quently tested on follow-up data across ten timepoints
(2461 responses). The best-performing OLS model (mod-
el F in the original publication) includes eight MSIS-29
items and age and sex. To apply the Hawton et al. [12]
mapping in this study, the MSIS-29 version 1 scores were
re-scored to match the 4-point scale of version 2, by
merging the categories ‘quite a bit’ and ‘moderately’ as
described in Sect. 2.3.2.
2.3.2.2 Condition-Specific Multiple Sclerosis Impact Scale
Preference-Based Measure (MSIS-PBM) (Dutch) The
MSIS-PBM was derived from version 1 of the MSIS-29. A
full description of the development of the measure can be
found elsewhere [8]. Prior to valuation, the instrument was
rescaled to a 4-point scale following Rasch analysis. Based
on results of the Rasch analysis, psychometric properties
and consultation of an expert neurologist, eight items of the
MSIS-29 were used to describe 100 health states that were
subsequently valued with the TTO method by a Dutch
general population sample (n = 402). The values for health
states not included in the TTO study were estimated using
OLS regressions. The included items related to problems
with balance, being clumsy, limitations in social and lei-
sure activities at home, difficulties in using hands in
everyday tasks, having to cut down on work or other daily
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activities, feeling mentally fatigued, feeling irritable impa-
tient or short tempered, and problems concentrating. The
instrument has utility values ranging from 1 to 0.42.
2.3.2.3 Condition-Specific Eight-Dimensional Multiple
Sclerosis Impact Scale (MSIS-8D) (UK) The MSIS-8D
[6] was also derived from the MSIS-29, but from version 2.
The MSIS-8D uses eight items of the MSIS-29 version 2
that take into account physical limitations, social and lei-
sure time limitations, being stuck at home, having to cut
down on work or daily activities, feeling mentally fatigued,
feeling irritable, having problems concentrating and feeling
depressed. Compared to MSIS-PBM it does not include
problems with balance, being clumsy and difficulties in
using hands. The MSIS-8D was converted to a preference-
based instrument through a TTO study with 1702 respon-
dents from the UK general population who valued 169
health states. The resulting instrument has utility values
ranging from 0.882 to 0.08. The answer categories of the
MSIS-29 version 1, which is included in the risk-sharing
database, were re-scaled from 12,345 to 12,334 to match
the design of the MSIS-8D, which is based on MSIS-29
version 2, similar to the approach of the Hawton et al. [12]
mapping algorithm.
2.3.3 Comparison of MSIS-29 Items Included in the Utility
Algorithms
Table 1 compares which items of the MSIS-29 (ver-
sions 1 and 2) have been included in the algorithms used
to calculate utility values. It shows that all algorithms
have included items from both the physical and the psy-
chological subscale of the MSIS-29, but that none of the
instruments are exactly similar despite similar develop-
ment methods for both the condition-specific instruments
and the mappings. This could be due to the use of dif-
ferent datasets and different versions of MSIS-29, expert
advice or choices of the researchers during the develop-
ment process.
2.4 Analyses
Equivalence of the three sources of utility values
incorporated in the model were compared using paired
t tests. The results of the Markov model are reported in
terms of 2005 costs, QALYs and ICERs. The model is
run using the literature-based utility values of the orig-
inal Markov model in order to enable comparison of
results of the replicated and original model. The effect of
applying EQ-5D, mapped EQ5D and MSIS-PBM and
MSIS8D utilities is then presented, for which the
deterministic results are supplemented with a proba-
bilistic sensitivity analysis.
2.4.1 Probabilistic Sensitivity Analysis
Probabilistic sensitivity analyses were not part of the
original published model but were added for this study.
Mean ICERS were calculated following probabilistic sen-
sitivity analysis with 5000 Monte-Carlo simulations.
Distributions were assigned to the costs of symptom
management and to the utilities. Costs were varied using a
gamma distribution and an assumed SE of 5 % of the mean
cost value. Utilities were varied using a beta distribution
and observed SEs in the UK risk-sharing scheme monitor-
ing study.
2.4.2 Scenario Analyses
Three scenario analyses were run. The first scenario anal-
ysis tested the hypothesis that the findings of this study do
not hold if the HR-QOL in the worst health state is as poor
as identified by EQ-5D. If this hypothesis holds, it shows
that the tendency of both regression-based mapping algo-
rithms and condition-specific instruments to overestimate
the HR-QOL of patients in poor health is a key driver of
inflated ICERs. The hypothesis was tested by setting the
utility value of health state EDSS4 equal to that of EQ-5D.
The second scenario tested whether alternative recoding of
the MSIS-29 version 1 to the MSIS-29 version 2, required
for the application of the MSIS-8D tariff and the Hawton
et al. [12] mapping algorithm, altered findings. In one
alternative, the ‘quite a bit’ category was merged with the
‘extremely’ category, rather than merging the ‘quite a bit’
category with the ‘moderate’ category which would have
been the most logical merge following Rasch analysis of
the MSIS-29. As a last scenario analysis, an alternative
mapping model by Hawton et al. [12] from the same
publication was applied (mapping model B).
3 Results
The EQ-5D-, mapped EQ-5D- and condition-specific
(MSIS-PBM and MSIS-8D)-based utility values per EDSS
health state as derived from the risk-sharing monitoring
scheme are presented in Table 2, alongside the utility
values applied in the original Markov model. In the paired
t test comparing Dutch mapped and observed EQ-5D val-
ues, values differed significantly for EDSS3 (t = 2.1,
p = 0.03) and EDSS4 (t = 2.7, p = 0.02). Observed Dutch
EQ-5D and MSIS-PBM values differed significantly for all
health states (t[ 3.6, p\ 0.05) except for EDSS1.
Looking at the UK values, EQ-5D health state values
estimated with the Versteegh et al. [10] mapping algorithm
did not differ significantly from observed EQ-5D health
states, except for EDSS4 (t = 2.1, p = 0.05). For the
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Hawton et al. [12] model F, only EDSS4 was not signifi-
cantly different (t = 0.6, p = 0.55). The condition-specific
MSIS-8D values differed significantly for UK EQ-5D
values (t[ 3.2, p\ 0.01) for all health states except
EDSS2 (t = 0.27, p = 0.78).
Compared with symptom management, the incremental
costs of subcutaneous glatiramer acetate were US$25,277.
When populated with the utility values in the original
study, subcutaneous glatiramer acetate gained 0.13 QALYs
and had an associated ICER of US$195,065 compared with
Table 1 29-Item Multiple Sclerosis Impact Scale items included in utility algorithms
Item
#
MSIS-29 items MSIS-8D
[6]
MSIS-
PBM [8]
Versteegh et al.
mapping [10]
Versteegh et al.
mapping [10]
Hawton et al.
mapping [12]
Country UK Dutch Dutch UK UK
Version of MSIS-29 Version
2
Version 1 Version 1 Version 1 Version 2
Physical impact scale
1 Do physically demanding tasks 9
2 Grip things tightly 9
3 Carry things 9 9
4 Problems with your balance 9 9
5 Difficulties moving about indoors 9 9
6 Being clumsy 9 9 9
7 Stiffness 9
8 Heavy arms and/or legs
9 Tremor of your arms or legs 9
10 Spasms in your limbs 9 9 9
11 Your body not doing what you want it to
do
12 Having to depend on others to do things
for you
13 Limitations in social and leisure
activities at home
9 9
14 Being stuck at home more than you
would like
9
15 Difficulties using your hands in
everyday tasks
9 9 9
16 Having to cut down time spent on
work/daily activities
9 9 9
17 Problems using transport 9
18 Taking longer to do things 9
19 Difficulty doing things spontaneously
20 Needing to go to the toilet urgently
Psychological impact scale
21 Feeling unwell 9 9 9
22 Problems sleeping 9
23 Feeling mentally fatigued 9 9
24 Worries about your MS 9
25 Feeling anxious or tense
26 Feeling irritable, impatient or short-
tempered
9 9 9
27 Problems concentrating 9 9
28 Lack of confidence 9
29 Feeling depressed 9 9 9
Total number of MSIS-29 items included 8 8 9 10 8
MSIS-8D eight-dimensional Multiple Sclerosis Impact Scale, MSIS-29 29-item Multiple Sclerosis Impact Scale, MSIS-PBM Multiple Sclerosis
Impact Scale Preference-Based Measure
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incremental costs of US$57,174, 0.22 QALYs gained and
an ICER of US$258,465 in the original publication, indi-
cating differences in mortality that could not be replicated
from the published data.
When QALYs were computed with data from EQ-5D,
mapped EQ-5D and the condition-specific instrument, the
following results were found: 0.14 QALYs were gained
when computed with Dutch EQ-5D utility data (0.16 with
UK utilities), 0.10 with mapped Dutch EQ-5D (0.13 with
UK Versteegh et al. [10] mapping and 0.14 with Hawton
et al. [12] mapping) and 0.09 QALYs were gained when
computed with utility data from the MSIS-PBM (0.095
with UK MSIS-8D). Deterministic and probabilistic ICERs
for all instruments are reported in Table 3. Excluding
productivity costs in the UK models did not alter the
outcome.
The mean ICER after probabilistic sensitivity analysis
using Dutch values was US$180,783 (SE = 21,376) with
EQ-5D-based values (US$147,306 [SE = 17,597] with UK
values), US$246,071 (SE = 22,636) with mapped EQ-5D
values (US$193,327 [SE = 17,401] with mapped Ver-
steegh et al. [10] UK values and US$169,383
[SE = 14,412] with Hawton et al. [12] mapping) and
US$289,814 (SE = 20,115) with MSIS-PBM-based values
(US$265,372 [SE = 27,591] with MSIS-8D). The 5000
ICERS of the Monte-Carlo simulation for both the UK and
the Dutch results are plotted in Fig. 2a, b and the associated
resulting cost-effectiveness acceptability curves for both
the UK and The Netherlands are presented in Fig. 3a, b.
The hypothesis of the first scenario analysis was con-
firmed in the Dutch model: by setting the value of the worst
health state of the mapped utilities and the condition-
specific utilities equal to that of EQ-5D, the difference
between the ICERs was reduced to US$7000. In the UK
model, the MSIS-8D-based ICER was still approximately
US$20,000 higher than the mapped and EQ-5D-based
ICERs. The second scenario analysis, with the alternative
coding of MSIS-29, increased the ICER, suggesting that
the alternative coding did not alter the conclusion of this
study. Applying mapping model B rather than model F
increased the ICER and hence did not alter the conclusion
of this study.
4 Discussion
Mapped and condition-specific utility values are consid-
ered to be a valid alternative to EQ-5D values in technol-
ogy appraisals in the UK and The Netherlands. While
authorities such as NICE request that they be informed
about the effect of using these alternatives on the ICER,
such a comparison is often not possible as the alternative
methods can only be applied when EQ-5D is either absent
or not appropriate. This study used EQ-5D (Dutch and UK
Table 2 Utilities EDDS1 EDDS2 EDDS3 EDDS4 Relapse 1 Relapse 2
Bell et al. [16] values 0.82 0.68 0.53 0.49 0.73 0.59
Dutch utilities
N 369 554 278 22
EQ-5D-3L utilities 0.74 0.63 0.52 0.33 0.65 0.55
SE 0.01 0.01 0.02 0.06
Mapped EQ-5D Versteegh et al. [10] 0.74 0.63 0.55 0.47 0.65 0.54
SE 0.01 0.01 0.01 0.03
MSIS-PBM utilities 0.75 0.66 0.59 0.55 0.65 0.57
SE 0.01 0.01 0.01 0.02
UK utilities
N 367 555 278 21
EQ-5D-3L utilities 0.71 0.58 0.44 0.19 0.62 0.49
SE 0.01 0.01 0.02 0.09
Mapped EQ-5D Versteegh et al. [10] 0.71 0.58 0.46 0.33 0.62 0.49
SE 0.01 0.01 0.01 0.05
Mapped EQ-5D Hawton et al. [12] 0.68 0.55 0.41 0.23 0.57 0.46
SE 0.01 0.01 0.01 0.03
MSIS-8D utilities 0.68 0.58 0.51 0.42 0.59 0.49
SE 0.01 0.01 0.01 0.04
Bold indicates a significant difference from EQ-5D at p\ 0.05
EDSS Expanded Disability Status Scale, MSIS-8D eight-dimensional Multiple Sclerosis Impact Scale,
MSIS-PBM Multiple Sclerosis Impact Scale Preference-based Measure, SE standard error
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Table 3 Deterministic and probabilistic incremental cost-effectiveness ratios for symptom management versus glatiramer acetate
Incremental
costs ($US)
Incremental
QALYsa
Deterministic
ICER ($US)
Probabilistic
ICER ($US)
% difference
vs. EQ-5D
Dutch utilities
EQ-5D-3L utilities 25,277 0.14 182,291 180,783
Mapped EQ-5D Versteegh et al. [10] 25,277 0.1 245,363 246,071 36
MSIS-PBM utilities 25,277 0.09 289,514 289,814 60
UK utilities
EQ-5D-3L utilities 25,277 0.16 153,476 140,736
Mapped EQ-5D Hawton et al. [12] 25,277 0.14 170,771 169,383 20
Mapped EQ-5D Versteegh et al. [10] 25,277 0.13 194,445 193,327 37
MSIS-8D utilities 25,277 0.1 265,342 265,372 89
ICER incremental cost-effectiveness ratio, MSIS-8D eight-dimensional Multiple Sclerosis Impact Scale, MSIS-PBM Multiple Sclerosis Impact
Scale Preference-based Measure, QALYs quality-adjusted life-years
a Rounded values
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planes: a Dutch and b UK.
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tariff), mapped EQ-5D (Dutch and UK mapping models)
and condition-specific utility values (Dutch and UK
instruments) taken from the same patient sample in a
hypothetical Markov model for relapsing-remitting MS
patients and showed that the ICERs differed substantially
when applying alternative sources of utilities.
This study was conducted in the context of the UK and
Dutch guidelines for economic evaluations, which both
prefer a uniform assessment of HR-QOL with EQ-5D
[2, 4]. When EQ-5D is demonstrably inappropriate, con-
dition-specific-utility instruments are accepted by the UK
and Dutch guidelines. The condition-specific instruments
applied here include dimensions not included in EQ-5D
(fatigue and cognition) and have advantages (increased
discriminatory properties) and disadvantages (floor effect
for MSIS-PBM and floor and ceiling effect for MSIS-8D
compared to EQ-5D). The consequence of these disad-
vantages is demonstrated in this study through a
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remarkably higher ICER of the condition-specific instru-
ments. This finding highlights the importance of having
strict criteria for determining the ‘inappropriateness’ of
EQ-5D in the context of health economic modelling that
places the most emphasis on the absolute difference in
utility between health states. The EQ-5D instrument may
seem inappropriate and lack face validity in some condi-
tions, or even have unfavourable psychometric properties,
but condition-specific instruments may underestimate the
total QALY gain due to a reduced scope of severity. The
results of this study also confirm the specification of the
guidelines that mapping to EQ-5D is preferred over con-
dition-specific alternatives in the absence of EQ-5D, as the
ICERs based on mapped EQ-5D better compare with
ICERs based on EQ-5D and, hence, contribute to a uniform
assessment of benefit.
The foremost explanation for the increase of the ICER
when using mapped and condition-specific utility values is
the smaller absolute difference between utility values of the
different health states in the Markov model, particularly for
the two poorer health states EDSS3 and EDSS4, for which
mapped and condition-specific utility values were higher
than EQ-5D. The scenario analysis showed that the higher
utility values in the EDSS4 state are a main driver of the
difference between ICERs. This shows that the over-pre-
diction of patients in poor health by mapping models, and
the generally higher values of condition-specific utility
instruments, have a large impact on technology appraisals
in the UK and The Netherlands.
Over-prediction of low utility values in OLS mapping
models is frequently observed [21, 22] and its impact on
the observed QALY gain has also been described [23].
Here it is shown once more that the inability of mappings
based on OLS regression algorithms to adequately capture
the utility of patients in poor health is problematic and can
even cause incorrect decisions in health technology
appraisals: mapped utilities may suggest that health would
be displaced with a positive reimbursement decision, while
this is merely an artefact of an unsuccessful estimation
method.
It was expected that the condition-specific MSIS-PBM
and MSIS-8D would be better at identifying improvements
in quality of life than EQ-5D. MSIS-PBM has been
demonstrated previously to be more sensitive to change
than EQ-5D in EDSS categories 3–5 [8] and did not
demonstrate a ceiling effect compared to EQ-5D. However,
as mentioned in Sects. 1 and 2, this improved sensitivity is
accompanied by a floor effect of both measures compared
to EQ-5D. For example, while the lowest utility value of
MSIS-8D is lower than that of MSIS-PBM (0.08 vs. 0.42),
not many patients actually reach such a state, explaining
the high mean value of patients in poor health. For MSIS-
PBM, the largest total utility decrement for the very ill is
0.58 (and, hence, a theoretical minimum utility value of
0.42) compared with 1.329 for the Dutch tariff of EQ-5D
[13]. As a consequence, the value for the poorest EDSS
health states is rather high. This high floor value is also
observed in the SF-6D and in several other condition-
specific preference-based measures [24–26] and might be
particularly influential in lifetime models where patients
deteriorate over time and hence reach a health state asso-
ciated with the floor value. While the MSIS-PBM and the
MSIS-8D might have smaller variance than EQ-5D,
demonstrated in the size of the ICER cloud after proba-
bilistic sensitivity analysis in Fig. 2a, b, it is the absolute
differences that have the largest impact on the ICER.
The observation that mapped and condition-specific
utility values inflate the ICER is not generalisable to
technology appraisals of life-saving/-extending interven-
tions or to Markov models with very short time horizons. If
an intervention would prolong life, and the mapped and
condition-specific utility values are higher on average than
EQ-5D utility values for patients in poor health, the addi-
tional life-years are assigned a larger QALY gain. The
long-term nature of MS, combined with no effect of
medication on survival, increase the difference between the
seven ICERs calculated for this study. If a model has a very
short time horizon, such as in cost-effectiveness analyses
performed alongside clinical trials, not all patients reach
the very poor EDSS states, decreasing the difference
between EQ-5D, mapped EQ-5D and condition-specific
utilities. As such, it could be that the effects here would not
be replicated in economic evaluations alongside a clinical
trial. It is even conceivable that a trial-based economic
evaluation with a short time horizon would produce results
opposite to those observed here as such an evaluation does
not require the grouping of patients in Markov health
states. However, it should be noted that guidelines call for
economic evaluations that are able to capture all relevant
costs and effects of a treatment to a patient, which gener-
ally requires time horizons that are much longer than the
trial period, especially for long-term conditions such as
MS. Therefore, the effects observed here are likely to be
observed in economic evaluations of MS that are accept-
able to reimbursement authorities.
When compared with the utility estimates applied in this
study, the utility estimates of the original study are high
and resemble MSIS-PBM utilities, as shown in Table 2.
The utilities in the original Bell et al. [16] study were taken
from the literature by the authors of the study. The first
cited source in that study is Prosser et al. [27], which
applied the standard gamble method in 67 members of the
general public of the USA to value six MS health states
with ten attributes, of which the worst health state was
related to EDSS score 8. The health state that represented
EDSS score 8 had a mean utility score of 0.491. The second
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cited study was a study report by Kobelt et al. [28], who
used the three-level version of EQ-5D in combination with a
non-final version of the US tariff as well as the UK tariff in
1909 MS patients. Utilities were reported in three categories:
mild, moderate and severe, of which the severe category
consists of patients with an EDSS score[6.5. This category
had a mean utility of 0.698 with the US tariff and 0.368 with
the UK tariff. The lowest possible value of the US tariff is –
0.109 [29]. The study noted an under-representation of
EDSS category 8 and above. The third cited study did not
contain utility values [30]. Standard gamble utilities are
generally higher than TTO-based utilities due to probability
weighting, loss aversion and scale compatibility [31]. Given
these sources of the utility values for the literature-based
model, the difference from the utility values used here based
on the TTO-valued EQ-5D and MSIS-PBM is understand-
able. The ICER using the utility values from the literature
was in between the EQ-5D-based ICER and the mapped and
MSIS-PBM-based ICER, mostly because of the larger range
of the utility values, i.e. the difference between the best
health state and the worst health state in the model, which
allows a larger effect.
A limitation of this study is that the Markov model from
the literature was not fully replicated as not all information
could be reproduced from the published article. Contact with
the authors from the original paper was sought on separate
occasions but not established. While the ICER is rather
similar to that of the replicated study, the difference between
the total QALYsgained and total incremental costs indicate a
systematic difference between the originalmodel and the one
replicated for this study. A crucial variable seems to be total
mortality, which for both studies was taken from 2005 US
life tables and a 0.000952monthly probability of progressing
from EDSS4 to death. The key difference between this study
and the published study was a fixed effectiveness rate rather
than long-term prediction models. In the original study,
disease progression increased over time, causing patients to
progress faster to the third and fourth EDSS health state in
which costs and the probability of death are larger. Also, the
transition probabilities of relapse rates and drug use in
relapse states could not be fully replicated from the original
publication and if the interpretation was not correct, this will
also impact the ICER. Hence, it is of importance to stress the
hypothetical nature of the absolute value of the ICERs pro-
duced in this study. However, the relative rather than abso-
lute difference between the MSIS-PBM-based ICER and the
EQ-5D-based ICER is unlikely to be affected by these
parameters.
Another limitation of this study is that the Markov model
was based on EDSS health states, and only on four merged
categories, rather than, for example, a separate health state
for all EDSS scores. First, a Markov model based on EDSS
health states is inherently limited to the discriminatory
properties of EDSS, which are arguably limited as it is a
mainly mobility-based assessment of quality of life. Second,
using only a limited number of EDSS states (effectively
grouping all EDSS categories into four states) reduces the
potential for the condition-specific instruments to show
increased sensitivity. For example, as measured with MSIS-
PBM, the difference in average utility values between EDSS
categories 3 and 5 is 0.05 with MSIS-PBM, while EQ-5D is
not able to pick up that improvement. This means that, had a
Markov model been used with all EDSS states, the MSIS-
PBM would be able to capture the benefit of a drug that
delays patients’ transitions between EDSS categories 3, 4
and 5. It is, however, unlikely that such a design would alter
the conclusions of this study. The additional benefit that
could be captured between EDSS categories 3 and 5 is a
utility of 0.05, which is much smaller than the difference
between the utility values of the fourth and worst EDSS
Markov health state (which is 0.14). This means that the
improved sensitivity of the instrument has a smaller impact
on the outcome of economic evaluations than its reduced
scope of severity. Hence, it is unlikely to offset the differ-
ence in the ICERs between EQ-5D and MSIS-PBM, even
when the model had had a separate state for all EDSS cat-
egories to best capture the increased sensitivity of the con-
dition-specific instruments. In general, it would be important
to see if the results demonstrated here are replicated in other
health economic models for MS.
The two condition-specific instruments in MS applied
here have disadvantages that seem to outweigh their
increased sensitivity, at least in the context of economic
evaluations in MS with a lifetime time horizon. Regarding
the future of HR-QOL assessment in MS, a future avenue of
research that may be fruitful is adding relevant MS dimen-
sions (i.e. fatigue) to the descriptive system of EQ-5D and
assigning a specific utility decrement to those dimensions.
5 Conclusion
The overestimation of quality of life of patients with MS by
mapped EQ-5D or condition-specific utility values, relative
to observed EQ-5D, increases the ICER substantially in a
Markov model with a lifetime time horizon for MS.
Acknowledgments The author would like to thank Saskia de Groot,
Laura Burgers and Pieter van Baal of the institute for Medical
Technology Assessment (iMTA) of Erasmus University of Rotterdam
for sharing their suggestions for this study.
Compliance with Ethical Standards
The research was not externally funded.
Disclosure Matthijs Versteegh is a member of the EuroQoL
Research Foundation.
Impact on the ICER of Using Alternatives to EQ-5D in a Markov Model for MS 1143
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM,
O’Riordan J. Incidence and prevalence of multiple sclerosis in the
UK 1990–2010: a descriptive study in the General Practice
Research Database. J Neurol Neurosurg Psychiatry.
2014;85(1):76–84.
2. National Institute for Health and Care Excellence. Guide to the
methods of technology appraisal 2013. London: NICE; 2013.
http://publications.nice.org.uk/pmg9. Accessed 7 Jan 2016.
3. Brazier J, Rowen D. NICE DSU technical support document 11:
alternatives to EQ-5D for generating health state utility values.
Report by the Decision Support Unit. Sheffield: Decision Support
Unit; 2011. http://www.nicedsu.org.uk/TSD11%20Alternatives%
20to%20EQ-5D_final.pdf. Accessed 1 June 2016.
4. Zorginstituut Nederland. Richtlijn voor het uitvoeren van
economische evaluaties in de gezondheidszorg. Diemen: Zor-
ginstituut Nederland; 2015.
5. Brazier J, Tsuchiya A. Preference-based condition-specific mea-
sures of health: what happens to cross programme comparability?
Health Econ. 2010;19(2):125–9.
6. Goodwin E, Green C, Spencer A. Estimating a preference-based
index for an eight-dimensional health state classification system
for multiple sclerosis. Value Health. 2015;18(8):1025–36.
7. Kuspinar A, Mayo NE. Do generic utility measures capture what
is important to the quality of life of people with multiple scle-
rosis? Health Qual Life Outcomes. 2013;11:71.
8. Versteegh M, Leunis A, Uyl-de Groot C, Stolk E. Condition-
specific preference-based measures: benefit or burden? Value
Health. 2012;15:504–13.
9. Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of
disease, functional status, and relapses on the utility of people with
multiple sclerosis in the UK. Value Health. 2007;10(1):54–60.
10. Versteegh MM, Leunis A, Luime JJ, Boggild M, Uyl-de Groot
CA, Stolk EA. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-
5D. Med Decis Mak. 2012;32(4):554–68.
11. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and
quality of life of patients with multiple sclerosis in Europe.
J Neurol Neurosurg Psychiatry. 2006;77(8):918–26.
12. Hawton A, Green C, Telford C, Zajicek J, Wright D. Using the
Multiple Sclerosis Impact Scale to estimate health state utility
values: mapping from the MSIS-29, version 2, to the EQ-5D and
the SF-6D. Value Health. 2012;15(8):1084–91.
13. Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Buss-
chbach JJV. The Dutch tariff: results and arguments for an
effective design for national EQ-5D valuation studies. Health
Econ. 2006;15(10):1121–32.
14. Kobelt G, Jo¨nsson L, Henriksson F, Fredrikson S, Jo¨nsson B.
Cost-utility analysis of interferon beta-1b in secondary
progressive multiple sclerosis. Int J Technol Assess Health Care.
2000;16(3):768–80.
15. Nuijten MJ, Hutton J. Cost-Effectiveness Analysis of interferon
beta in multiple sclerosis: a Markov process analysis. Value
Health. 2002;5(1):44–54.
16. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley
J, Johnson K. Cost-effectiveness of four immunomodulatory
therapies for relapsing-remitting multiple sclerosis: a Markov
model based on long-term clinical data. J Manag Care Pharm.
2007;13(3):245–61.
17. Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T,
Dobson C, et al. Multiple sclerosis risk sharing scheme: two year
results of clinical cohort study with historical comparator. BMJ.
2009;339:b4677.
18. Dolan P. Modeling valuations for the EuroQol health states. Med
Care. 1997;35:1095–108.
19. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The
Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based
outcome measure. Brain. 2001;124(5):962–73.
20. Hobart J, Cano S. Improving the evaluation of therapeutic
interventions in multiple sclerosis: the role of new psychometric
methods. Health Technol Assess. 2009;13(12):iii, ix–x, 1–177.
21. Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies
mapping (or cross walking) non-preference based measures of
health to generic preference-based measures. Eur J Health Econ.
2010;11(2):215–25.
22. Versteegh MM, Rowen D, Brazier JE, Stolk EA. Mapping onto
Eq-5 D for patients in poor health. Health Qual Life Outcomes.
2010;26(8):141.
23. Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir
KR. Do estimates of cost-utility based on the EQ-5D differ from
those based on the mapping of utility scores? Health Qual Life
Outcomes. 2008;14(6):51.
24. Stolk EA, Busschbach JJV. Validity and feasibility of the use of
condition-specific outcome measures in economic evaluation.
Quality Life Res. 2003;12(4):363–71.
25. Yang Y, Brazier JE, Tsuchiya A, Young TA. Estimating a pref-
erence-based index for a 5-dimensional health state classification
for asthma derived from the asthma quality of life questionnaire.
Med Decis Mak. 2011;31(2):281–91.
26. Brazier JE, Roberts J, Platts M, Zoellner YF. Estimating a pref-
erence-based index for a menopause specific health quality of life
questionnaire. Health Qual Life Outcomes. 2005;15(3):13.
27. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and
community preferences for treatments and health states in mul-
tiple sclerosis. Mult Scler. 2003;9(3):311–9.
28. Kobelt G, Berg J, Atherley D, Hadjimichael O. Costs and quality
of life in multiple sclerosis: a cross-sectional study in the United
States. Neurology. 2006;66(11):1696–702.
29. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D
health states: development and testing of the D1 valuation model.
Med Care. 2005;43(3):203–20.
30. Kobelt G. Economic evidence in multiple sclerosis: a review. Eur
J Health Econ. 2004;5:s54–62.
31. Bleichrodt H. A new explanation for the difference between time
tradeoff utilities and standard gamble utilities. Health Econ.
2002;11:447–56.
1144 M. Versteegh
